Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients

被引:40
作者
Barkin, Jodie A. [1 ]
Westermann, Amy [2 ]
Hoos, William [2 ]
Moravek, Cassadie [2 ]
Matrisian, Lynn [2 ]
Wang, Hongwei [3 ]
Shemanski, Lynn [3 ]
Barkin, Jamie S. [1 ]
Rahib, Lola [2 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Gastroenterol, Miami, FL 33136 USA
[2] Pancreat Canc Act Network, Manhattan Beach, CA USA
[3] Canc Res & Biostat, Seattle, WA USA
关键词
pancreatic cancer; pancreatic enzymes; pancreatic enzyme replacement therapy; pancreatic exocrine insufficiency; symptom alleviation; weight loss; RELEASE CAPSULES CREON; CONTROLLED TRIAL; INSUFFICIENCY; SURVIVAL; PANCREATICODUODENECTOMY; RESECTION;
D O I
10.1097/MPA.0000000000001330
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives Pancreatic cancer (PC) and its treatments can result in pancreatic exocrine insufficiency that requires pancreatic enzyme replacement therapy (PERT). Appropriate PERT usage is during meals and snacks. The aim was to determine the frequency of appropriate use of PERT and its impact on symptom alleviation in PC through a patient-reported outcomes online platform. Methods Users in the Pancreatic Cancer Action Network's Patient Registry were prompted to answer a standalone questionnaire about their experience with PERT. Results Two hundred sixty-two users completed the PERT questionnaire (January 2016-January 2018). Patients who reported taking PERT with meals had higher alleviation of symptoms compared with those taking PERT prior to or after meals. Specifically, "feeling of indigestion," "light-colored or orange stools," and "visible food particles in stool" were significantly decreased. Patients taking PERT with meals reported weight gain and less weight loss. Conclusions Of the 89% of PC patients prescribed PERT, 65% were prescribed PERT appropriately with all meals and snacks. Overall compliance with PERT administration guidelines was low (50% [105/208]). Improvement in symptoms significantly correlated with appropriate use of PERT. Increase in PC patient and provider education about appropriate PERT usage and administration is warranted.
引用
收藏
页码:780 / 786
页数:7
相关论文
共 25 条
[1]  
[Anonymous], PANCREAS
[2]  
Barkin JA, 2018, GASTROENTEROLOGY, V154, pS719
[3]  
BARKIN JS, 1982, CANCER-AM CANCER SOC, V50, P2189, DOI 10.1002/1097-0142(19821115)50:10<2189::AID-CNCR2820501035>3.0.CO
[4]  
2-N
[5]   Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature [J].
Bartel, Michael J. ;
Asbun, Horatio ;
Stauffer, John ;
Raimondo, Massimo .
DIGESTIVE AND LIVER DISEASE, 2015, 47 (12) :1013-1020
[6]  
Barugola G, 2007, J PANCREAS, V8, P132
[7]   Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region [J].
Bruno, MJ ;
Haverkort, EB ;
Tijssen, GP ;
Tytgat, GNJ ;
van Leeuwen, DJ .
GUT, 1998, 42 (01) :92-96
[8]   Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis [J].
de la Iglesia-Garcia, Daniel ;
Huang, Wei ;
Szatmary, Peter ;
Baston-Rey, Iria ;
Gonzalez-Lopez, Jaime ;
Prada-Ramallal, Guillermo ;
Mukherjee, Rajarshi ;
Nunes, Quentin M. ;
Dominguez-Munoz, J. Enrique ;
Sutton, Robert .
GUT, 2017, 66 (08) :1474-1486
[9]   Pancreatic cancer: Clinical presentation, pitfalls and early clues [J].
DiMagno, EP .
ANNALS OF ONCOLOGY, 1999, 10 :140-142
[10]   Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency:: a randomized, three-way crossover study [J].
Domínguez-Muñoz, JE ;
Iglesias-García, J ;
Iglesias-Rey, M ;
Figueiras, A ;
Vilariño-Insua, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (08) :993-1000